Filing Flows › Pfizer (PFE) › Q2 2026 › vs Q2 2025
Pfizer (PFE) Q2 2026 vs Q2 2025 (year over year)
Pfizer's revenue rose $381M (+3%) from $14.7B in Q2 2025 to $15.0B in Q2 2026.
Pfizer, Q2 2026: revenue $15.0B (+3% year over year), operating margin -4.3%, net loss $237M, operating cash flow $835M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 2.0% | -8.2% | +10.2 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $15.0B | $14.7B | $381M | +3% |
| Income tax benefit | $407M | −$141M | $548M | — |
| Net loss | $237M | −$2.9B | $3.2B | — |
| Costs & expenses | $15.7B | $14.7B | $1.0B | +7% |
| Operating costs | $15.7B | $11.6B | $4.1B | +35% |
| Cost of revenue | $4.1B | $3.8B | $314M | +8% |
| Research & development | $2.8B | $2.5B | $327M | +13% |
| SG&A | $3.4B | $3.4B | −$4.0M | -0.1% |
| Other operating costs | $5.4B | $1.9B | $3.5B | +181% |
| Operating cash sources | $1.9B | $1.8B | $43.0M | +2% |
| Depreciation & amortization | $1.6B | $1.6B | −$3.0M | -0.2% |
| Share-based compensation | $249M | $203M | $46.0M | +23% |
| Net loss absorbed | $237M | −$2.9B | $3.2B | — |
| Working capital & other | $799M | $5.3B | −$4.5B | -85% |
| Operating cash flow | $835M | −$582M | $1.4B | — |
| Free cash flow (OCF − capex) | $302M | −$1.2B | $1.5B | — |
| Capital expenditures | $533M | $618M | −$85.0M | -14% |
Questions
How much did Pfizer's revenue grow year over year in Q2 2026?
Pfizer's revenue rose $381M (+3%) from $14.7B in Q2 2025 to $15.0B in Q2 2026.